Following positive Phase IIb trial results, RH5.1/Matrix-M has the potential to be the first blood-stage malaria vaccine brought to market.
Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.
Alumis has revealed encouraging results from a Phase I clinical trial of tyrosine kinase 2 (TYK2), A-005, in healthy subjects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback